19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 1
SS-01-TB diagnostic network assessment: innovative and comprehensive TB diagnostic network assessment model
event_note Wednesday, 21 Oct 2020
query_builder 18:15 - 19:45 | Event time (GMT+1)
query_builder 18:15 - 19:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-01-TB diagnostic network assessment: innovative and comprehensive TB diagnostic network assessment model
*Please scroll down for more information*
Organised by: The United States Agency for International Development / Infectious Disease Detection and Surveillance (IDDS) project

The tuberculosis (TB) diagnostic network assessment is an innovative, holistic and comprehensive way to assess a country's dedicated TB diagnostic network. It's a country driven activity which involves local and external TB experts. This joint activity assesses the functionality of a country's TB diagnostic, in line with the national strategic plan and the End TB strategy. This assessment and review will help the country to identify key gaps and recommendations as well as help to strengthen a comprehensive TB diagnostic network with strong underlying health systems. 

Target audience 1: Doctors, Nurses, Lab technicians
Target audience 2: Clinicians, TB programme managers, activists
Target audience 3: TB project managers, NGOs



18:15 - 18:20: Introduction


18:20 - 18:35: Improving TB diagnostic access by the TB diagnostic network assessment model The Tuberculosis (TB ) diagnostic network assessment (DNA) is a country driven process that assesses the functionality of the national TB diagnostic network and system. It helps in determining the system’s capacity to meet the needs of the country’s national TB strategic plan (NSP) for achieving the goals outlined in the End TB strategy. The TB DNA reviews, holistically, the diagnostic network and current practices and algorithms; identifies challenges that prevent the diagnostic network from performing efficiently and effectively and proposes evidence-based interventions to improve the overall ability of the diagnostic network to meet the goals and targets of the NSP.

Amy Piatek

18:35 - 18:50: The TB diagnostic network assessment tool presentation The use of an assessment tool, with semi-quantitative scoring, for the country to identify the stage of various aspects of the diagnostic network and to describe current capabilities and identify key areas for improvement. Verification of the self-assessed staging, using a set of standardised tools and checklists, and including site visits to a selection of sites. Conducted by an experienced group of international laboratory experts with support from in-country lab and TB experts.

Thomas Shinnick

18:50 - 19:05: TB diagnostic network assessment: data and spatial analysis The spatial TB diagnostic network analysis will be used to inform tuberculosis diagnostic network assessment (TB DNA) planning on a selection of regions to be assessed during the in-country visit  - brief the TB DNA teams about TB diagnostic network situation (coverage, access and effectiveness) prior to/at the beginning of the assessment visit; inform conclusions and support the development of recommendations by the TB DNA team during the assessment visit; develop baseline network scenarios, which can be refined during the TB DNA in-country visit, based on findings and assumptions for additional diagnostic instruments, relocated instruments, altered specimen referral linkages or other.

Manuela Rehr

19:05 - 19:20: Infectious Disease Detection and Surveillance project support to countries on the TB diagnostic network assessment The Infectious Disease Detection and Surveillance (IDDS) project is currently working closely with countries’ national tuberculosis (TB) control programmes to reinforce TB and drug-resistant TB diagnostics for all eligible patients. The TB diagnostic network assessment (TB DNA) has already been conducted in India, Uganda and Zimbabwe. The upcoming countries for 2020 are Tanzania, Viet Nam and Bangladesh. We are also working with relevant stakeholders to conduct this assessment in Mozambique and Burma. The support from IDDS is based on the respect of human rights and that access to all these diagnostic technologies should be available, regardless of a population’s income or cultural, racial, gender, religious or ethnic inclination.

Inoussa Zabsonre

19:20 - 19:45: Q&A session


Loading...
Channel 2
SS-02-Shining a new light on TB diagnostics
event_note Wednesday, 21 Oct 2020
query_builder 18:15 - 19:45 | Event time (GMT+1)
query_builder 18:15 - 19:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-02-Shining a new light on TB diagnostics
*Please scroll down for more information*
Organised by: Cepheid

The overall objective of the session will support the audience to gain deeper insights on latest innovations in TB diagnostics. 
The panelists will walk through novel technologies to improve drug-susceptibility testing, host response concepts as well as clinical insights to leverage available diagnostic tools.
* CE-IVD. In Vitro Diagnostic Medical Device. Product not available in the United States.

18:15 - 18:25: Introduction


18:25 - 18:45: Behind the scenes – Innovations in TB diagnostics Dr. Gnanashanmugam will share insights about the innovation behind the Xpert® MTB/XDR assay* and Cepheid’s technology.

Devasena Gnanashanmugam

18:45 - 19:05: Evaluation of Xpert® MTB/XDR* and possibilities of integration into the National diagnostic algorithm – the South African perspective Dr. Omar will present the first clinical evaluation of the recently launched Xpert® MTB/XDR* assay in South Africa.
* CE-IVD. In Vitro Diagnostic Medical Device. Product not available in the United States.

Shaheed Vally Omar

19:05 - 19:25: Demonstrating the power of heterogeneity: from discovery to point-of-care using public data for tuberculosis diagnosis Dr. Khatri will speak about host response gene signatures in Tuberculosis and share further insights.

Purvesh Khatri

19:25 - 19:45: Using available TB diagnostics to Guide Patient Management – A Clinical Perspective Prof. Kon will share his experience as a clinical expert in how to leverage diagnostic tools for patient management.  
 

Onn Min Kon

Loading...
Channel 2
SS-04-Innovative Medicines Initiative Antimicrobial Resistance Accelerator: a new public-private partnership to tackle antimicrobial resistance
event_note Thursday, 22 Oct 2020
query_builder 9:45 - 10:45 | Event time (GMT+1)
query_builder 9:45 - 10:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-04-Innovative Medicines Initiative Antimicrobial Resistance Accelerator: a new public-private partnership to tackle antimicrobial resistance
*Please scroll down for more information*
Organised by: Uppsala University and Carlos III University
The Innovative Medicines Initiative (IMI) Antimicrobial Resistance (AMR) Accelerator is a recently formed consortium of over 50 partners, unified by a common goal of developing new tools and therapeutics to fight resistant pathogens, with a particular focus on targeting tuberculosis (TB) and Gram-negative bacteria.   The initiative is comprised of three core pillars: COMBINE, a capability building network; ERA4TB, a TB drug development  network; and portfolio building networks that include the projects TRIC-TB and RespiriTB. The scope of the AMR Accelerator is broad;  aiming to consolidate expertise under one structure to tackle AMR and accelerate the progression of antibiotics towards the clinic.

09:45 - 09:55: Innovative Medicines Initiative Antimicrobial Resistance Accelerator: structure and strategy Presentation of the consortium supporting all the projects in the Antimicrobial Resistance Accelerator: COMBINE

Karen O´Dwyer

09:55 - 10:10: The European Regimen Accelerator for Tuberculosis (ERA4TB): concept, vision and progress Presentation of the consortium looking at progressing antitubercular drugs within the Antimicrobial Resistance Accelerator: ERA4TB

Stewart Cole

10:10 - 10:20: Innovative Medicines Initiative Antimicrobial Resistance Accelerator: a new public-private partnership to tackle the antimicrobial resistance issue worldwide: Tric TB Presentation of Tric TB: portfolio building networks of the Antimicrobial Resistance Accelerator.

Michel Pieren

10:20 - 10:30: New approaches to targeting the respiratory chain of M. tuberculosis Presentation of RespiriTB: portfolio building network of the Antimicrobial Resistance Accelerator.

Meindert Lamers

10:30 - 10:45: Q&A session


Loading...
Channel 1
SS-03-Approaches to improve TB case finding and treatment outcomes in children
event_note Thursday, 22 Oct 2020
query_builder 9:45 - 10:45 | Event time (GMT+1)
query_builder 9:45 - 10:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-03-Approaches to improve TB case finding and treatment outcomes in children
*Please scroll down for more information*
Organised by: Johnson & Johnson Global Public Health

Confirming the diagnosis of tuberculosis (TB) is a major challenge, especially in very young children. For drug-resistant TB, this means that children may end up on suboptimal therapy or even on no therapy at all.
Researchers around the world have explored how to improve the diagnosis of TB in children. In this satellite session, we plan to facilitate the sharing of learnings from paediatric TB experts on how healthcare providers and  national TB programmes can improve the identification of children with TB so that they receive appropriate care.

09:45 - 10:00: Epidemiology of childhood TB and drug-resistant TB Prof Seddon will describe the current epidemiology of childhood tuberculosis

James Seddon

10:00 - 10:15: Symptom-based approach to diagnosing childhood TB. What next? Variable presentations of tuberculosis (TB) among children present a unique challenge. In many instances, objective diagnostic  modalities (eg sputum culture or molecular methods) are suboptimal so physicians have to rely on 'clinical' judgement,  supplemented by epidemiological information, to make a diagnosis. Canwe do better?

Ben Marais

10:15 - 10:30: Research agenda to improve TB treatment outcomes in children The world has made some progress in the treatment of drug-resistant tuberculosis (DR-TB) disease. It is imperative that children not be  just a footnote to this progress, but that they are included in efforts to find more effective and better tolerated drug regimen for DR-TB. 
Prof Hesseling will discuss current gaps in the treatment of childhood DR-TB, some of the ongoing research activities to address these gaps  and the way forward to ensure that children benefit from advances in the treatment of DR-TB.

Anneke Hesseling

10:30 - 10:45: Challenges in diagnosing and treating TB in children Children have been neglected in the fight against tuberculosis (TB). Despite being the number one infectious disease killer, TB does  not feature on the child survival agendas. There is need to elevate childhood TB to the top of the agenda and we do what  needs to be done to ensure that no child unnecessarily dies from TB, if we truly intend to eliminate TB.

Farhana Amanullah

Loading...
Channel 3
SS-05-Leave no one behind: we can defeat COVID-19 and latent TB infection together
event_note Thursday, 22 Oct 2020
query_builder 9:45 - 10:45 | Event time (GMT+1)
query_builder 9:45 - 10:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-05-Leave no one behind: we can defeat COVID-19 and latent TB infection together
*Please scroll down for more information*
Organised by: QIAGEN
Global health experts are working to slow the COVID-19 pandemic – but responding to COVID-19 has also forced disruption of existing TB control programs around the globe. QIAGEN is committed to fighting COVID-19 and TB, developing innovative new testing solutions so that no one is left behind in the battle against pandemic lung diseases. Join our interactive symposium as we discuss QIAGEN's evolving solutions in two parts:
Part 1. QIAreach QuantiFERON-TB: A simple and accurate solution for decentralized TB infection screening
Currently in development, the QIAreach QuantiFERON-TB is a field-friendly, portable latent TB testing solution that will expand access to TB testing where it's needed the most. QIAGEN's assay development team will introduce the test and provide a scientific review of early performance data. This will be followed by first-hand experiences from ongoing trials of the test conducted in Zambia.

Part 2. Tackling TB and COVID-19 together: From centralized to decentralized testing
Stop TB and the WHO have highlighted the overlapping symptoms and risk groups shared by COVID-19 and TB. QIAGEN's Dr. Masae Kawamura will discuss shared disease etymologies and introduce QIAGEN's portfolio of cutting-edge solutions for both centralized and decentralized testing. Centralized solutions include: QuantiFERON-TB Gold Plus (TB) and QIAstat-Dx Respiratory SARS-CoV-2 Panel (SARS-CoV-2). Decentralized solutions include: QIAreach QuantiFERON-TB (TB), QIAreach Anti-SARS-CoV-2 Total (not available in all markets) and QIAreach SARS-CoV-2 Antigen Test (SARS-CoV-2).
Products and product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
QIAreach QuantiFERON-TB and QIAreach SARS-CoV-2 Antigen are currently under development and coming soon. QIAreach QuantiFERON-TB is intended for high-TB-burden countries.

09:45 - 09:50: Introduction


09:50 - 09:57: QIAreach QuantiFERON-TB: a simple and accurate solution for decentralised TB infection screening Currently in development, the QIAreach QuantiFERON-TB is a field-friendly, portable latent tuberculosis (TB) testing solution that will expand access to TB testing where it's needed the most. QIAGEN's assay development team will introduce the test and provide a scientific review of early performance data. This will be followed by first-hand experiences from ongoing trials of the test conducted in Zambia.

Kwame Shanaube

09:57 - 10:11: Tackling TB and COVID-19 together: from centralised to decentralised testing Stop TB and the World Health Organization have highlighted the overlapping symptoms and risk groups shared by COVID-19 and tuberculosis (TB). QIAGEN's Dr. Masae Kawamura will discuss shared disease etymologies and introduce QIAGEN's portfolio of cutting-edge solutions for both centralised and decentralised testing. Centralised solutions include: QuantiFERON-TB Gold Plus (TB) and QIAstat-Dx Respiratory SARS-CoV-2 Panel (SARS-CoV-2). Decentralised solutions include: QIAreach QuantiFERON-TB (TB), QIAreach Anti-SARS-CoV-2 Total (not available in all markets) and QIAreach SARS-CoV-2 Antigen Test (SARS-CoV-2).

Masae Kawamura

Loading...
Channel 4
SS-07-Advancements in the TB diagnostics pipeline: FIND and NDWG annual  symposium
event_note Thursday, 22 Oct 2020
query_builder 18:15 - 19:45 | Event time (GMT+1)
query_builder 18:15 - 19:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-07-Advancements in the TB diagnostics pipeline: FIND and NDWG annual  symposium
*Please scroll down for more information*
Organised by: FIND and NDWG
Tuberculosis (TB) diagnostics are needed to detect exposure, diagnose disease and drug resistance, and to monitor improvement under treatment in both primary healthcare and laboratory settings. The Foundation for Innovative New Diagnostics (FIND) and the Stop TB  Partnership’s New Diagnostics Working Group (NDWG) bring to you the latest developments in TB diagnostics R&D. You will hear from leading  global experts on the advancements in the TB diagnostics pipeline, improvements in the detection of drug-resistant TB, next-generation  sequencing and the diagnosis of TB infection.

18:15 - 18:20: Introduction

Daniela Cirillo

18:20 - 18:40: TB diagnostics pipeline update: 2020 and beyond While we can accelerate progress, we cannot end the tuberculosis (TB) epidemic with the tools that we have today. We need rapid, and  affordable, non-sputum based tests for diagnosis or triage, accurate drug-susceptibility testing for critical medicines, and better tools to detect TB infection and testing for risk of progression to active disease. We are working with our partners and donors to make easy-to-use, robust, reliable and highly accurate tests a reality in routine clinical settings, particularly at the lower levels of care. Our R&D efforts are  focused on areas of critical unmet needs. Our session brings to you the most comprehensive update on the TB diagnostics pipeline in 2020  and beyond.

Morten Ruhwald

18:40 - 18:50: Recent advances in the diagnosis of drug-resistant TB The development and implementation of rapid molecular diagnostics for tuberculosis (TB) drug-susceptibility testing (DST) is critical to inform patient treatment and to prevent the emergence and spread of resistance. We report results from two recently completed  multicentre diagnostic accuracy studies: 1. the Xpert MTB/XDR assay (Cepheid, USA) for detecting resistance to isoniazid (INH), ethionamide (ETH), fluoroquinolones (FQs) and secondline injectables,amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), and 2) the Molbio Truenat molecular diagnostic assays for detection of M.tb and RIF-resistance.

Adam Penn-Nicholson

18:50 - 19:00: Seq&Treat project: bringing next generation TB care to underserved communities Targeted next-generation sequencing (tNGS) has the potential to revolutionise tuberculosis (TB) drug-susceptibility testing (DST) as it can provide fast, accurate, safe and comprehensive results to inform clinical decision-making for current and upcoming drug-resistant TB  treatment regimens. The Unitaid-funded Seq&Treat project is designed to generate evidence and boost in-country capacity to support  global policy and adoption of end-to-end tNGS solutions for affordable, scalable and rapid TB DST. We report results from analytical validation  of three tNGS end-to-end solutions for detecting resistance to rifampicin (RIF), isoniazid (INH), ethionamide (ETH), fluoroquinolones (FQs),  second-line injectables (amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), and pyrazinamide (PZA), among others.

Anita Suresh

19:00 - 19:10: Improving interpretation of pncA gene mutations for sequencing-based drug-susceptibility testing of pyrazinamid Pyrazinamide (PZA) is a key first line anti-tuberculosis (TB) drug, which is also recommended in regimens for treating isoniazid-resistant TB and for the completion of multidrug/rifampicin-resistant TB regimens. Because of the lack of appropriate infrastructure and technical difficulties,  phenotypic drug-susceptibility testing (pDST) for PZA is not carried out in many high-incidence countries and PZA is, therefore, used  empirically. The World Health Organization has concluded that sequencing of pncA may be the most reliable method to rule-in PZA resistance.  An increasing number of low-incidence countries are introducing routine next-generation sequencing from the first positive culture for all TB  cases. In this scenario, the question becomes how to interpret the pncA sequence data and whether pDST is still needed. This study  introduces a strategy to guide the initial treatment decision and a set of rules regarding confirmatory testing and the resolution of discordant  results.

Paolo Miotto

19:10 - 19:20: Advancing the TB prevention agenda Diagnosis of tuberculosis infection (TBI) remains challenging. To estimate the public health impact and cost-effectiveness  of screening for, and treating incipient TB (ITB), a deterministic, dynamictransmission model was developed by the New Diagnostics Working Group, assuming an ITB test which meets the World Health Organization target product profile. It predicted that, to be cost-effective, the cost of an ITB test will differ widely between countries,  depending on the costing approach and control strategy. Additionally, a systematic review was performed to synthesise current evidence on the  diagnostic value of novel in vivo specific skin tests for TBI compared to currently available in vitro IGRA tests and the PPD-TST. Test  performance of novel skin tests did not differ significantly to that reported for IGRA. Finally, a framework for evaluation of new  immunodiagnostic tests for TBI was developed to facilitate their standardised evaluation. The framework describes the principles to be  considered when evaluating new tests for TBI.

Alberto Matteelli

19:20 - 19:45: Q&A session


Loading...
Channel 2
SS-06-Discussion on COVID-19: is there a role for the 100-year-old BCG vaccine?
event_note Thursday, 22 Oct 2020
query_builder 18:15 - 19:45 | Event time (GMT+1)
query_builder 18:15 - 19:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-06-Discussion on COVID-19: is there a role for the 100-year-old BCG vaccine?
*Please scroll down for more information*
This session has been made possible by an educational grant from AJVaccines

For almost a century, BCG vaccination has been widely used to protect against tuberculosis (TB). Non-specific effects, such as reducing overall infant mortality or the observation of fewer respiratory infections, have been attributed to the vaccine. Underlaying immune mechanisms have been proposed. Early on in the COVID-19 pandemic, epidemiological data suggested that populations with longstanding BCG vaccination may be less affected. Also, some homology between SARS-CoV-2 and Mycobacterium bovis, has been described. Several clinical trials in first responders and vulnerable populations are evaluating whether BCG mitigates the clinical course of COVID-19. Investigators will discuss the context and details of their trials.

18:15 - 18:20: Introduction by Camille Locht


18:20 - 18:40: COVID-19: is there a role for the 100-year-old BCG vaccine? Denmark For almost a century, BCG vaccination has been widely used to protect against tuberculosis (TB). Non-specific effects, such as  reducing overall infant mortality or the observation of fewer respiratory infections, have been attributed to the vaccine. Underlaying immune  mechanisms have been proposed. Several clinical trials in first responders and vulnerable populations are evaluating whether BCG mitigates the clinical course of COVID-19. Investigators will discuss the context and details of their trials.

Christine Benn

18:40 - 18:50: BCG vaccination to reduce the impact of COVID-19 in Australian healthcare workers following coronavirus exposure: BRACE trial Healthcare workers are at increased risk of contracting COVID-19, caused by SARS-CoV-2. Currently, there are no  vaccines or proven preventative interventions available to protect healthcare workers. The Bacille Calmette-Guérin (BCG) vaccine is  designed to protect against tuberculosis (TB). However it also boosts immunity to protect against other infections. The purpose of the BRACE  trial is to find out whether BCG vaccination protects against COVID-19 or reduces severity of COVID-19 in healthcare workers.

Nigel Curtis

18:50 - 19:00: COVID-19: is there a role for the 100-year-old BCG vaccine? The South African study For almost a century, BCG vaccination has been widely used to protect against tuberculosis. Non-specific effects, such as  reducing overall infant mortality or the observation of fewer respiratory infections, have been attributed to the vaccine. Underlaying immune  mechanisms have been proposed.
Several clinical trials in first responders and vulnerable populations are evaluating whether BCG mitigates the clinical course of COVID-19.
Investigators will discuss the context and details of their trials.

Andreas Diacon

19:00 - 19:10: COVID-19: is there a role for the 100-year-old BCG vaccine? The Dutch study For almost a century, BCG vaccination has been widely used to protect against tuberculosis. Non-specific effects, such as  reducing overall infant mortality or the observation of fewer respiratory infections, have been attributed to the vaccine. Underlaying immune  mechanisms have been proposed.
Several clinical trials in first responders and vulnerable populations are evaluating whether BCG mitigates the clinical course of COVID-19.
Investigators will discuss the context and details of their trials.

Reinout van Crevel

19:10 - 19:20: COVID-19: is there a role for the 100-year-old BCG vaccine? Extension of the BRACE trial in Brazil For almost a century, BCG vaccination has been widely used to protect against tuberculosis. Non-specific effects, such as  reducing overall infant mortality or the observation of fewer respiratory infections, have been attributed to the vaccine. Underlaying immune  mechanisms have been proposed.
Several clinical trials in first responders and vulnerable populations are evaluating whether BCG mitigates the clinical course of COVID-19.
Investigators will discuss the context and details of their trials.

Julio Croda

19:20 - 19:45: Discussion Q&A session chaired by Camille Locht


Loading...
Channel 1
SS-08-Role of policy and community in addressing Latent TB in India: leaving no one behind
event_note Friday, 23 Oct 2020
query_builder 9:45 - 10:45 | Event time (GMT+1)
query_builder 9:45 - 10:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-08-Role of policy and community in addressing Latent TB in India: leaving no one behind
*Please scroll down for more information*
Organised by: KHPT, NTEP, USAID

Latent TB infection is a clinical condition defined by a positive tuberculin skin test in patients who have no clinical or radiological evidence of active disease. While India carries the highest burden of TB, with an estimated 2.69 million cases in 2018, there exist a high number of people with latent TB infection, with nearly 40% of the country’s population harboring this ‘silent infection’. In India, patients are not only burdened by their illness, but are concomitantly afflicted by tremendous social stigma due to being tested TB positive. This in turn has detrimental effects on the patients’ health and well-being, and is also one of the main drivers for negative health-seeking behavior. To this already dire situation are a large number of patients who are more at-risk of contracting TB, and less likely to seek or receive medical help for the same. In this light, we want to utilize a human-centric approach to best address the needs, create policy changes and provide access to treatment to the most vulnerable section of society, those who have been suffering in silence for far too long.


09:45 - 09:49: Introduction


09:49 - 10:06: Role of community in addressing LTBI in India

H.L Mohan

10:06 - 10:16: Leveraging community networks for addressing LTBI

Karuna Sagili

10:16 - 10:26: Role of Policy in addressing LTBI in India

Dalbir Singh

10:26 - 10:34: The key role of global partnerships: USAID and LTBI in India

Reuben Swamickan

10:34 - 10:37: Role of TB survivors in addressing LTBI in India

Sunitha David

Loading...
Channel 2
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
event_note Friday, 23 Oct 2020
query_builder 18:15 - 19:45 | Event time (GMT+1)
query_builder 18:15 - 19:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-09-Testing to turn the COVID-19 pandemic: the opportunity for TB
*Please scroll down for more information*
Organised by: FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria.
FIND and The Global Fund are co-convenors of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar – part of a  global collaboration to accelerate the development, production and equitable access to new COVID-19 tools including diagnostics. In addition  to developing new tests, the ACT Accelerator Diagnostics Pillar aims to strengthen low- and middle-income countries’ ability to procure, import, distribute tests  and manage data to assist governments in decision making. Tests developed to enable rapid diagnosis of tuberculosis (TB) are now being  used to diagnose COVID-19. Could global diagnostic networks and new COVID-19 tools be utilised to combat TB in the future?

18:15 - 18:19: Introduction


18:19 - 18:53: Panel discussion: TB, COVID-19 and ACT-A Dx – mitigating the impact and protecting TB gains Diagnostics are critical to any health response and essential to limit the spread of disease. However, greater innovation and  funding are needed to ensure tests can be deployed quickly and easily to everyone who needs one. In deploying new tools, programmes must  aim for integrated service delivery to balance supply and deployment constraints. FIND and The Global Fund are co-convenors of the Access  to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar under which 50 new diagnostic tests have been evaluated. A new rapid antigen test  will soon be ready for roll out and 17 million tests have been delivered to low-and middle-income countries. The ACT-Accelerator experience provides vital lessons on  what a blueprint for successful pandemic preparedness and response could look like for diagnostics. What lessons can we learn for tuberculosis (TB), which is already experiencing the knock-on impact of COVID-19, and how do we protect our gains in TB while successfully beating the pandemic?

Catharina Boehme
John Nkengasong
Kuldeep Singh Sachdeva
Peter Sands

18:53 - 19:03: TB tests being 'repurposed' for COVID-19: experience with Truenat, GeneXpert, digital X-rays and next-generation  sequencing The COVID-19 pandemic has seen existing diagnostics for tuberculosis (TB) being repurposed or used to diagnose COVID-19. Cepheid  Inc’s GeneXpert® MTB/RIF - for the rapid diagnosis of TB and detection of rifampicin-resistance - is being used to run a newly developed  COVID-19 test. Similarly, Indian diagnostic manufacturer, Molbio, whose Truenat™ test was recently endorsed by the World Health Organization received approval  from India’s regulatory authority for a Truenat COVID-19 test, expanding the number of existing diagnostics platforms repurposed for COVID-19. Additionally, digital chest Xray can be deployed along with artificial intelligence-based tools for both TB and COVID-19.  Leveraging ongoing efforts in enabling next-generation sequencing solutions for drug-resistant TB detection under the Unitaid-funded  Seq&Treat project, FIND has compiled a landscape and a preliminary assessment of sequencing utility and capacity in low-and middle-income countries for COVID-19 surveillance and management. We’ll share in-country implementers' experience repurposing TB tests for COVID-19.

Morten Ruhwald

19:03 - 19:13: Ending TB amid the COVID-19 pandemic: a community-led response The COVID-19 pandemic has had tremendous impact on tuberculosis (TB) programmes and activated disruptions along the care spectrum, from screening to diagnosis to the treatment of people with TB. While efforts have been made through the contribution of the Global Fund and stakeholders worldwide, impactful gains were undone. While barriers were being addressed there was an increase in the barriers faced, including  access to services, along with heightened stigma and the dual stigma of COVID-19 and TB. There is a need for meaningful engagement and for strengthening community engagement and linkages in order to address barriers collectively and to find solutions. Community systems and community-led  monitoring can support the implementation of catch-up plans so that efforts in finding the missing people with TB can be reinforced and barriers can be mitigated.
This session highlights experiences of civil society and partners and their role in the mitigation of the impact of COVID-19 on TB and on the road ahead.

Carol Nawina (Nyirenda) Kachenga

19:13 - 19:23: Access to TB diagnostic services during COVID-19: experience from South Africa In many of the countries most heavily affected by HIV, tuberculosis (TB) and malaria, the knock-on impact of COVID-19 on these three  diseases, in terms of incremental deaths, may outweigh the direct impact of the virus. The Global Fund is already witnessing the impact of  COVID-19 on the fight against HIV, TB and malaria across the countries where itinvests. For example, TB laboratory services are under acute  pressure, with 20% experiencing high or very high levels of disruption, with many of the advanced diagnostics instruments put in place to  diagnose TB now being used for testing for COVID-19. We’ll hear from South Africa – a country with a high TB and HIV burden which is now addressing  the deadly pandemic - on scale-up of COVID-19 testing and integration of testing services for COVID-19 and TB.

Wendy Stevens

19:23 - 19:45: Q&A session


Loading...
Channel 1
SS-10-Role of new age technologies of artificial intelligence and machine learning in pandemic of TB and Covid 19 – lessons learnt
event_note Saturday, 24 Oct 2020
query_builder 18:15 - 19:45 | Event time (GMT+1)
query_builder 18:15 - 19:45 | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-10-Role of new age technologies of artificial intelligence and machine learning in pandemic of TB and Covid 19 – lessons learnt
*Please scroll down for more information*
Organised by: DeepTek Inc.

Novel coronavirus disease (COVID-19) and tuberculosis (TB) are two key challenges that have severely unsettled the world. We focus on the role of digital chest X-ray and High-Resolution CT chest for screening.  Artificial Intelligence (AI) enabled, instant triage and smart reporting ensures fast turn-around times for resource constrained units. Innovating TB screening in times of COVID-19 pandemic can help deal with the two challenges in one setting. Expert panelists from leading hospitals, governmental organizations, NGO’s share their valuable experiences to showcase how AI is a force multiplier for public health screening.
Target audience: government bodies, non- profit organizations/ non- government organizations, foundations/trusts, hospitals

18:15 - 18:20: Introduction


18:20 - 18:35: Our experience in COVID-19 diagnosis from Mumbai India using artificial intelligence augmented radiological imaging to improve turnaround time of reporting. Dr Patkar will discuss the role of AI in busy tertiary care setups reorganised into designated COVIDd Care centers due to enhanced number of cases. How Hospitals can benefit by the value add created by AI and enhance patient throughput.

Deepak Patkar

18:35 - 18:50: High volume tertiary care COVID-19 instant triage and response using Machine learning and smart structured reporting Role of AI in Diagnosis of Pandemics and Corona Virus Like scenarios. The Present value of disruptive innovations. Considering the looming health concern of COVID-19, how can AI and Disruptive healthcare innovators partner with hospitals, research organisations and Government work on opportunities for early diagnosis to move beyond assessing the illness by clinical symptoms. AI radiology can deploy the tools and algorithms to encourage early intervention and monitor complications preventing high morbidity. It would be very useful to humanity if the stakeholders in current crisis with present affected population can their clinical data, learnings, knowledge to help co create a fast prototype to market and pre-empt future pandemic panic. Are we mature to share the learnings?

Avinash Nanivadekar

18:50 - 19:05: How resource constrained economies are using low cost imaging and AI for TB screening. Co-testing for TB and COVID-19, is this a reality? The world was already facing the slow pandemic of TB, when COVID-19 stuck. The global target for TB elimination is set at 2030 and India has set the target of TB elimination by 2025. How do these targets match up in the era of COVID-19? Can new age technologies support in keeping these targets intact?

Akash Dey

19:05 - 19:20: Prospects of use of artificial intelligence in national TB elimination programme Services of National TB elimination Programme got impacted due to COVID-19 pandemic in terms of decline in notification etc. NTEP have undertaken various initiatives to reclaim lost notifications including policy of bidirectional screening for TB and COVID simultaneously.
COVID-19 have provided an opportunity to address all respiratory ailments in comprehensive, synergistic fashion. It may augment response, save resources more over may contribute to health system strengthening.
Use of Artificial intelligence in various components of programme specially diagnostics provide an opportunity to deal with TB & COVID in comprehensive manner.
Application of AI in radiological screening for TB, COVID and other respiratory infections is in tandem of broader principles of Pulmonary Approach to Lung Health (PAL) and may significantly contribute to Health system strengthening. It may equip health system for future respiratory outbreaks.

Sandeep Bharaswadkar

19:20 - 19:35: Computer-aided reading (CAR) software for TB screening: learnings from Viet Nam This presentation will highlight the community-based CXR screening which FIT and partners have conducted in Viet Nam and the CAR evaluations which have been conducted with the resultant data.  This will include a landscape analysis for 13 different CAR software, a training and evaluation scheme for a CAR software program to triage normal images away from human read and an assessment of additional/marginal yields of TB from sputum collection based on CAR results.

Andrew Codlin

19:35 - 19:45: Q&A session


Loading...
Processing. Please wait.
Loading...